We have previously shown in a large X-linked pedigree that a deletion removing the dystrophin muscle promoter, the first muscle exon and part of intron 1 caused a severe dilated cardiomyopathy with no associated muscle weakness. Dystrophin expression was present in the muscle of affected males and transcription studies indicated that this dystrophin originated from the brain and Purkinje cell isoforms, upregulated in this skeletal muscle. We have now studied dystrophin transcription and expression in the heart of one member of this family. In contrast to the skeletal muscle, dystrophin transcription and expression were absent in the heart, with the exception of the distal Dp7l dystrophin isoform, normally present in the heart. The 43-and 50-kD dystrophin-associated proteins were severely reduced in the heart, despite the presence of Dp7l, but not in skeletal muscle. The absence of dystrophin and the down-regulation of the dystrophin-associated proteins in the heart accounted for the severe cardiomyopathy in this family. The mutation present in these males selectively affects dystrophin expression in the heart; this could be secondary to the removal of cardiac-specific regulatory sequences. This family may represent the first example of a mutation specifically affecting the cardiac expression of a gene, present physiologically in both the skeletal and cardiac muscles. (J. Clin. Invest. 1995. 96:693-699.)
Introduction
Dilated cardiomyopathies are characterized by ventricular dilatation and impaired systolic function. They are the most common form among the various types of primary myocardial disorders characterized by impaired ventricular function. The prevalence of dilated cardiomyopathies has recently been estimated at 36 .5/100,000 the United States (1) . The majority of them A proportion of these forms, estimated to be at least 20% of the total, show a clear Mendelian inheritance (2) , and various patterns of inheritance, including autosomal dominant (3, 4) , autosomal recessive (5) , and X-linked forms (6) (X-linked dilated cardiomyopathy, XLDCM'), have all been documented.
There is apparently no clinical difference between these various familial and sporadic forms, and their identification relies on careful examination of the pedigree and, in addition, the study of first degree relatives. Molecular biological techniques have now enabled dissection of this group of disorders, and linkage to the dystrophin gene has been found in two X-linked pedigrees (7) , and mutations in this gene described both in XLDCM families (8) and sporadic cases (9) .
An autosomal dominant form has also been recently mapped to chromosome ipI -Iqi (10) . The fact that not all autosomal dominant families with dilated cardiomyopathy are linked to chromosome 1 suggests the existence of at least a second locus (10) (Mestroni, unpublished observation). This heterogeneity is not surprising, considering the number of genes that contribute to cardiomyocyte integrity and contractility. In the various reported XLDCM families in which a dystrophinopathy was demonstrated (7) (8) (9) , no muscle weakness nor clinical evidence of skeletal muscle involvement was found. Although under physiological circumstances dystrophin is expressed at equal levels in the skeletal and cardiac muscles, and one would therefore expect mutations in the dystrophin gene to equally affect both tissues, the families with XLDCM indirectly supported the concept that some mutations might primarily affect dystrophin expression in the heart. In the XLDCM cases in which a deletion of the dystrophin gene was found (8, 9) , the lack of availability of cardiac tissue made it impossible to compare dystrophin gene expression in the skeletal muscle with that in the heart. This only allowed one to speculate on the possible reasons for this peculiar disease course. In particular, it was unclear if a protein that could maintain its function in the skeletal muscle but not in the heart was produced or if the mutation selectively affected dystrophin expression only in the heart (11) . We have now been able to obtain a cardiac biopsy from one member of the XLDCM family we reported before (8) . We report here the comparative analysis of dystrophin transcription and expression in the skeletal muscle and heart of this individual. We found that no dystrophin was produced in his heart, with the exception of the Dp7l distal isoform (12, 13) . The dystrophin-associated-glycoproteins, or DAGs (14-16), al-1. Abbreviations used in this paper: BMD, Becker muscular dystrophy; cTnC, slow/cardiac troponin C; DAG, Dystrophin-associated-glycoprotein; DMD, Duchenne muscular dystrophy; XLDCM, X-linked dilated cardiomyopathy. though expressed in the skeletal muscle, were severely reduced in the heart, despite the Dp7l expression. Our results strongly suggest that the mutation found in this family selectively affects dystrophin expression in the heart but not in the skeletal muscle.
Methods
The XLDCM family ( Fig. 1 ) has previously been described in detail (8 33: 5' GACGGAAAATCCCAAAGAACTTGA 3', respectively), the L-type isoform (24) (L-promoter-exon 6, for the first PCR round, oligonucleotides 5' CTAGTTCTCCAAGCTCTACTCATG 3' and 5' ACCCAGCTCA GGAGAATC'l1lCA 3', respectively, while a reverse oligonucleotide located in exon 4, 5' ACATTGTTCAGGGCA-TGAACTCT 3', was used in the second PCR round). Oligonucleotides for amplifying the a2 laminin chain gene (25) (also referred to as merosin) were a) forward oligonucleotide 5' CTGTGATCAGTGCTGT CCAGGGATT annealing (60 s), and 720C extension (120 s), for 26 cycles. 9 jtl of the reactions were analyzed on 2.5% agarose gels containing 0.2 grams/ml of ethidium bromide prior to photography. A second round of PCR was performed when studying the transcription of the L-type promoter.
Results

Skeletal muscle biopsy
Histology. On muscle biopsy, a similar picture was found in all three affected individuals: there was some variability in fiber size with the presence of mildly hypertrophic and atrophic fibers, and a moderate increase in internal nuclei (Fig. 2 A) . There was no increase in interstitial connective tissue.
Immunocytochemistry. (a) Dystrophin and DAGs. Although all fibers were continuously labeled with antibodies to dystrophin and the 43-and 50-kD DAGs, the intensity of fluorescent labeling was paler than in control muscle, as judged by visual inspection ( (c) Utrophin. Antibodies to utrophin showed labeling of all blood vessels and moderate labeling of the sarcolemma of several fibers (Fig. 3 E) .
Cardiac biopsy Histological picture. The histological picture of the cardiac biopsy showed a marked variability of fiber size and severe fibrosis (Fig. 2 B) .
Immunocytochemistry. (a) Dystrophin and DAGs. No immunoreactivity was observed with antibodies directed towards the N-terminal (Fig. 2 D) and mid-rod-region of dystrophin (not shown). A weak but clear immunoreactivity was observed at the sarcolemma of each cardiomyocyte using a COOH-terminal anti-dystrophin antibody (Fig. 2 F) . This pattern of dystrophin expression suggests that this represent the Dp7l dystrophin isoform. Immunocytochemistry performed with antibodies to the 43-and 50-kD DAG showed a severe reduction of these two proteins, as judged by visual evaluation (Fig. 3, B and D) . (a) Merosin. Merosin immunolabeling was normal (not shown). (c) Utrophin staining showed marked increase in staining at the periphery of almost every cardiomyocyte (Fig. 3 F) .
Reverse transcription and PCR Co-amplification of the cDNA from normal skeletal and cardiac muscle using the oligomers for the mid-rod region (exons 30-33) of dystrophin and for the a2 laminin gene gave the expected size products in both tissues (Fig. 4) . Regarding the patient's tissues, amplification of both dystrophin and the a2 laminin chain gene was obtained in the skeletal muscle (Fig. 4) ; in the heart, however, no amplification of dystrophin could be obtained (Fig. 4) .
Regarding the transcription of the novel dystrophin L-isoform (24), no amplification was obtained after a single course of PCR in the various samples analyzed (normal skeletal and cardiac muscle, lymphocytes, Fig. 5) . A band of the expected size (also including exon two, and therefore in contrast to what previously reported) (24), was detectable only after a second round of PCR in the lymphocytes but not in the other tissues, including the patient's material (Fig. 5) .
The Dp71 mRNA was amplified from normal fetal muscle, Figure 2 . Cryostat sections of skeletal (A, C, and E) and cardiac (B, D, and F) muscle from a XLDCM family affected member, stained with the Gomori's trichrome (A and B), and immunolabeled with antibodies to the NH2-terminal region of dystrophin (C and D), and to the COOH-terminal region of dystrophin (E and F). Note the marked pathology in the heart compared with skeletal muscle, and the presence of dystrophin in skeletal muscle with both NH2 and COOH-terminal antibodies, in contrast to the absence of NH2-terminal dystrophin and only faint traces of COOHterminal dystrophin in the heart. A, B, C, and E, x180; D and F x250.
and at similar levels from adult cardiac muscle and from the heart biopsy of the XLDCM family member studied (Fig. 6) .
No amplification of the same transcript was detected in the skeletal muscle of various members of the XLDCM family, nor in normal skeletal muscle (Fig. 6 ).
Discussion
Dystrophin is a very large cytoskeletal protein expressed in all muscle types. While its localization is limited to the cytoplasmic surface of the sarcolemma in skeletal muscle, it is also expressed in the T tubules in the cardiac myofibers (27, 28) . Mutations in the dystrophin gene are responsible for both the severe Duchenne type muscular dystrophy (DMD) and its milder allelic variant Becker muscular dystrophy (BMD). In contrast to these two conditions, no clinical evidence of skeletal muscle involvement is present in families with a XLDCM secondary to a dystrophinopathy. Since in almost all these cases the muscle promoter is deleted (8, 9) , transcription of the muscle isoform should have theoretically been abolished. However, no muscle weakness was detected, and dystrophin was visualized using immunocytochemistry in the muscle of these patients (8, 9) . We have recently characterized the pattern of dystrophin transcription in our XLDCM family and have found that the brain and the Purkinje-cerebellar cell isoforms were expressed at high levels in the skeletal muscle of the affected males (11) . The overexpression of these two isoforms was therefore capable of preventing muscle degeneration. We have now also characterized the transcription of the recently described L-isoform (24) and shown that it does not play any significant role in normal muscle and heart, nor in this XLDCM family.
These studies, however, did not clarify the reason for the severe cardiac involvement in this XLDCM family. In particu- Figure 3 . Cryostat sections of skeletal muscle (A, C, and E) and cardiac muscle (B, D, and F) from a XLDCM family affected individual, immunostained with antibodies to the 43-kD (A and B) and the 50-kD (C and D) DAGs, and to utrophin (E and F). Note the mild reduction in intensity of the DAGs in skeletal muscle, but the more severe reduction in the heart. Utrophin is also expressed in both tissues, but at higher levels in the cardiac muscle. A, C, E, and F, x 180; B and D, x280. lar, the brain-type transcript has been shown to be physiologically expressed in the heart (11, 29) and its expression should therefore not have been affected by the deletion of the muscle promoter. In this report we demonstrate, however, that dystrophin was not detected immunocytochemically in the heart of the proband, using anti-dystrophin antibodies directed towards the NH2-terminal and mid-rod-domain region. In keeping with these results, no transcription for the same regions could be seen in the patient's heart.
Dystrophin is associated with a large oligomeric complex of sarcolemmal proteins, including a-dystroglycan which provides a link to the extracellular matrix component, laminin (14) (15) (16) . Previous studies have indicated that all of these DAGs are reduced in skeletal muscle of the mdx mouse (30) and in DMD (31) . In BMD the DAGs are only mildly to moderately reduced and there is a good correlation between the reduction of the DAGs and dystrophin and the severity of the phenotype (32, 33) .
Immunocytochemical study of the 43-and 50-kD DAGs performed in this family showed mildly reduced levels in the skeletal muscle of the affected males. The DAGs immunoreactivity, however, was considerably reduced in the heart, indicating once again that the absence of dystrophin leads to a deficiency in DAGs. The absence of dystrophin and the deficiency of the DAGs is likely to render the cardiomyocytes susceptible to necrosis and this can account for the severe fibrosis we found in the heart. The levels of utrophin found in the heart were similar to those found in the DMD skeletal muscle (34) . Despite its presence, however, utrophin did not provide a compensatory function and did not prevent the dystrophic process in the heart.
Immunocytochemistry performed in the heart using COOHterminal anti-dystrophin antibodies showed a weak but clear sarcolemmal staining in the cardiomyocytes. This signal most likely resulted from the expression of the dystrophin distal transcript Dp7l (12, 13, 26) which is expressed physiologically in the heart (13) . This hypothesis is suggested by the following and heart and from the same tissues from the XLDCM case.
observations: (a) there was no immunoreactivity with antibodies directed towards other dystrophin domains; (b) there was no transcription of the mid-rod-region of dystrophin; (c) we successfully amplified the Dp7l unique mRNA isoform from the cardiac biopsy of the patient.
Dp7l is the major DMD gene product in brain and other nonmuscle tissues. It is undetected in adult skeletal muscle (12, 26) but expressed in the heart (13) . The function of this DMD gene product is still unknown. The predicted amino acid sequence shows that Dp7l lacks the spectrin-like domain that confers a rod-shaped structure to dystrophin and it also lacks the NH2-terminal domain, which is assumed to bind actin. However, it contains the COOH-terminal domain, which is the most conserved domain of dystrophin, and the cysteine-rich domain, which shares homology with the Ca2+-binding domain of aactinin. Since the association of dystrophin with the DAGs is mediated partly by the cysteine-rich domain and partly by the COOH-terminal domain (15) , it is conceivable that Dp7l is also associated with the DAGs complex. In keeping with this hypothesis, Dp7l is associated with the plasma membrane in muscle (12, 35) , and co-localizes with the dystrophin glycoprotein complex adjacent to the Z-disk (13) . It has also been shown that overexpression of Dp7 1 in the skeletal muscle of transgenic mdx mouse is capable of restoring the DAGs levels (36, 37) .
In our study we have detected a significant down-regulation of the DAGs in the cardiac muscle of our XLDCM family, despite the expression of normal levels of the Dp71 protein.
The DAG levels in the heart of this affected male were similar to those found in the muscle of individuals with severe BMD, where some dystrophin, but not the Dp7l is expressed. Our result therefore indirectly suggests that the physiological levels of Dp71 partially contribute to the DAG binding in the heart. This is however not sufficient to avoid the onset and progression of the cardiac pathology. This might indicate that the role of Dp7l in the heart is different from that of dystrophin; the fact Dp7l lacks both the spectrin-like repeats and the actin-binding domain of dystrophin further reinforces this view. In view of the partial contribution of Dp7l to the DAG binding, it would be interesting to verify if the rare DMD patients with a mutation affecting the production of both the major dystrophin isoforms and Dp71 suffer from a more severe cardiomyopathy then patients with mutations affecting the major dystrophin isoforms in isolation. The complete absence of the major dystrophin isoforms in the heart in individuals that express them in the skeletal muscle has not been reported before. The pattern of dystrophin expression in the heart of these individuals is similar to that found in DMD, while in the skeletal muscle it is comparable with that of a very mild BMD. The most likely explanation for the mechanism of disease in this family is the removal of cis-acting sequences essential for transcription of dystrophin in the heart. It is of interest that these putative sequences had no role on the Dp71 transcription in the skeletal muscle and heart of our patient. In particular, the Dp7l mRNA levels in the heart of the patient were similar to those obtained in the control hearts; moreover, no upregulation of the Dp71 isoform was detected in the skeletal muscle of this individual, contrary to what found for both the brain and Purkinje-cells isoforms. These results indicate the absence of transcriptional interference between the 5' promoters and the Dp71 promoter. The same deduction can also be applied to the L-type isoform. As previously suggested (11), these putative regulatory sequences may lie within the very large first dystrophin intron (38) . Analysis of the sequence of this intron has shown regions of homology to various muscle specific regulatory elements, such as an "E box" (39) , a MEFi binding site (40) , and a MEF2 binding site (41) , all involved in binding or enhancing the function of various members of the helix-loop-helix protein family (42, 43) .
Although members of the helix-loop-helix family, such as MyoDi or MEF2, are not detected in heart, an "E box" has been found in the regulatory region of the human cardiac actin promoter and has been shown to be important for its expression in myocardiocytes (44) . Similarly, a MEF2 site has been identified in the regulatory region of several genes mainly expressed in the heart, such as the cardiac troponin T (45, 46) and rat cardiac myosin light chain-2 gene (47) .
Several genes expressed both in the cardiac and skeletal muscle have recently been shown to have distinct transcriptional pathways involved in the cardiac and skeletal muscle-specific gene expression. In this respect the slow/cardiac troponin C (cTnC) gene is expressed in adult cardiac and slow skeletal muscle (48) and only transiently in embryonic fast skeletal myotubes (49) . While the cTnC gene expression in embryonic skeletal muscle is regulated by a skeletal muscle-specific, developmentally regulated transcriptional enhancer located within the first intron of the gene, a distinct and independent transcriptional enhancer, located within the immediate 5' flanking region of the cTnC gene regulates its expression in the heart (50) .
It is therefore conceivable that a separate transcriptional pathway is responsible for dystrophin expression in the skeletal muscle and heart. The sequences we have already suggested might be responsible for driving dystrophin transcription in the heart, as well as others located in the large intron 1. Further studies aimed at characterizing in detail these putative sequences are still needed. This information will also be of value when designing gene therapy strategies for DMD.
In conclusion, our data suggest that the deletion found in our family with XLDCM selectively affects dystrophin expression in the heart but not in the skeletal muscle. The Dp71 dystrophin isoform, although expressed in the cardiac tissue, is not capable of maintaining adequate DAG levels and therefore of restoring dystrophin function. From our data it is also possible to hypothesize that other genes that are co-expressed in skeletal muscle and heart might also undergo selective transcriptional impairment in this latter tissue and therefore are potential candidates for autosomically inherited dilated cardiomyopathies.
